Silence Therapeutics plc Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
Silence Therapeutics plc (SLNCF) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum of 77.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum · last filed 2026-03-05
- Silence Therapeutics plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2025 was 77.50%, a 4.17% increase from fiscal 2024.
- Silence Therapeutics plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2024 was 74.40%, a 3.33% increase from fiscal 2023.
- Silence Therapeutics plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2023 was 72.00%, a 28.57% increase from fiscal 2022.
- Silence Therapeutics plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2022 was 56.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 12 month |
|---|---|
| 2025-12-31 | 77.50% 10-K · filed 2026-03-05 |
| 2024-12-31 | 74.40% 10-K · filed 2026-03-05 |
| 2023-12-31 | 72.00% 10-K · filed 2025-02-27 |
| 2022-12-31 | 56.00% 10-K · filed 2025-02-27 |